Cardax Reports Q2 2019 Results

Author's Avatar
Aug 15, 2019
Article's Main Image

- CHASE clinical trial progressing; interim review planned for September 2019

- $1,675,000 raised since beginning of Q2 2019

- ZanthoSyn® sell-through strong; top selling antioxidant nationwide at GNC in 2019

- ZanthoSyn® sell-in down in Q2 2019 but has increased in Q3 2019

- ZanthoSyn® retail expansion beyond GNC planned

PR Newswire